What's the diagnosis for ASX healthcare shares in 2025?

Do we have a healthy future in store?

| More on:
Medical or healthcare workers grasp hands in the universal expression of teamwork

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare shares have been a mixed bag in 2025, with some names outperforming the market by a wide margin while others have floundered.

The S&P/ASX 200 Health Care Index (ASX: XHJ), which tracks the sector's market performance, has climbed 7.75% this year to date.

This is behind the broader market represented by the S&P/ASX 200 Index (ASX: XJO), which is up nearly 11% over the same time.

But experts reckon ASX healthcare shares are poised to take centre stage in 2025. Could this signal value waiting to be unlocked? Let's see.

Outlook for ASX healthcare shares

Analysts and investment firms are bullish on the Australian healthcare sector's long-term fundamentals. This could be positive for ASX healthcare shares.

Earlier this year, Wilsons Advisory described the sector's outlook as "highly attractive", citing a combination of robust earnings growth and relatively low valuations.

Healthcare expenditure is also projected to surge over the coming years. The Federal Budget projected healthcare spending of $112.7 billion by FY25, increasing to $123 billion the following year.

Meanwhile, Fidelity International highlights the ageing population as a growth driver for healthcare companies.

It says the number of people aged over 65 is expected to double by 2050.

Healthcare has another notable structural driver: the global population aged over 65 will double by
2050 and the proportion of incomes we spend on keeping ourselves healthy will continue to grow.

Aussie investors are also jumping on board the healthcare gravy train.

According to investment firm VanEck's latest investor survey, ASX healthcare shares are in one of the top sectors Australians plan to target in 2025 (alongside technology).

The survey found that 77% of respondents were eyeing international equity exchange-traded funds (ETFs), with healthcare topping the list of sectors due to its defensive nature and growth potential.

Where are the opportunities?

According to VanEck, global and ASX healthcare shares have "significant, long-term growth potential" for investors.

The company says there are four primary ways to gain exposure to the space, namely businesses in the pharmaceutical, biotech, equipment and supply, and healthcare services domains.

VanEck also says diversification is key.

Investors can gain exposure to healthcare companies by buying shares in healthcare companies directly or via a fund or ETF which focuses on investing in the healthcare sector.

Meanwhile. analysts are bullish on two giants among fellow ASX healthcare shares.

Bell Potter rates CSL Ltd (ASX: CSL) a buy with a $345 price target, forecasting "above market" profit growth for the biotech giant.

ECP Asset Management also has long-term projections on CSL, being of $500 apiece by 2027.

ResMed Inc (ASX: RMD) is also rated highly by brokers. A total of 15 from 18 brokers covering the stock rate it a buy, according to CommSec.

Ord Minnett rates ResMed a buy, with a $40.05 per share price target. It projects profit growth of 13% from the respiratory device business in 2025.

Final thoughts

According to experts, ASX healthcare shares are well-positioned for 2025. Part of this is due to the outlook on the broader healthcare industry.

Meanwhile, analysts see plenty of earnings potential from companies within the sector.

Stepping back, healthcare is known as a 'defensive' industry because it is not strongly correlated to the ups and downs of the broader economy. In other words, healthcare is considered necessary in both good and bad economic times.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »